Summary: Heparin-dependent serine protease inhibitor acting in body fluids and secretions. Inactivates serine proteases by binding irreversibly to their serine activation site. Involved in the regulation of intravascular and extravascular proteolytic activities. Plays hemostatic roles in the blood plasma. Acts as a procoagulant and proinflammatory factor by inhibiting the anticoagulant activated protein C factor as well as the generation of activated protein C factor by the thrombin/thrombomodulin complex. Acts as an anticoagulant factor by inhibiting blood coagulation factors like prothrombin, factor XI, factor Xa, plasma kallikrein and fibrinolytic enzymes such as tissue- and urinary-type plasminogen activators. In seminal plasma, inactivates several serine proteases implicated in the reproductive system. Inhibits the serpin acrosin; indirectly protects component of the male genital tract from being degraded by excessive released acrosin. Inhibits tissue-and urinary-type plasminogen activator, prostate-specific antigen and kallikrein activities; has a control on the sperm motility and fertilization. Inhibits the activated protein C-catalyzed degradation of SEMG1 and SEMG2; regulates the degradation of semenogelin during the process of transfer of spermatozoa from the male reproductive tract into the female tract. In urine, inhibits urinary-type plasminogen activator and kallikrein activities. Inactivates membrane-anchored serine proteases activities such as MPRSS7 and TMPRSS11E. Inhibits urinary-type plasminogen activator-dependent tumor cell invasion and metastasis. May also play a non-inhibitory role in seminal plasma and urine as a hydrophobic hormone carrier by its binding to retinoic acid. [UniProtKB/Swiss-Prot Function]
These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service.
OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at firstname.lastname@example.org. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
* Delivery time in business days.Occasional delay may occur due to complexity of the constructs.
All shRNA Citations:
Mitochondrial damage and cholesterol storage in human hepatocellular carcinoma cells with silencing of UBIAD1 gene expression, Morales, CR;Grigoryeva, LS;Pan, X;Bruno, L;,
Molecular Genetics and Metabolism Reports Sep 2014
[UBIAD1] Transmembrane Domain Targeting Peptide Antagonizing ErbB2/Neu Inhibits Breast Tumor Growth and Metastasis, Arpel, A;Sawma, P;Spenlé, C;Fritz, J;Meyer, L;Garnier, N;Velázquez-Quesada, I;Hussenet, T;Aci-Sèche, S;Baumlin, N;Genest, M;Brasse, D;Hubert, P;Crémel, G;Orend, G;Laquerrière, P;Bagnard, D;,
Cell Rep Sep 2014
[ERBB2] PGC-1a mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis, LeBleu, VS;O'Connell, JT;Gonzalez Herrera, KN;Wikman, H;Pantel, K;Haigis, MC;de Carvalho, FM;Damascena, A;Domingos Chinen, LT;Rocha, RM;Asara, JM;Kalluri, R;,
Nat. Cell Biol. Sep 2014
[PPARGC1A] Leukocyte specific protein-1: A novel regulator of hepatocellular proliferation and migration deleted in human HCC, Koral, K;Paranjpe, S;Bowen, WC;Mars, W;Luo, J;Michalopoulos, GK;,
Hepatology Sep 2014
[ LSP1] Inhibition of tumor-associated avß3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo, Contois, LW;Akalu, A;Caron, JM;Tweedie, E;Cretu, A;Henderson, T;Liaw, L;Friesel, R;Vary, C;Brooks, PC;,
Angiogenesis Sep 2014
[ITG?3] Pannexin 1 and Pannexin 3 Channels Regulate Skeletal Muscle Myoblast Proliferation and Differentiation, Langlois, S;Xiang, X;Young, K;Cowan, BJ;Penuela, S;Cowan, KN;,
J. Biol. Chem. Sep 2014
[Panx3] TGF-ß1 mediates the radiation response of prostate cancer, Wu, CT;Hsieh, CC;Yen, TC;Chen, WC;Chen, MF;,
J. Mol. Med. Sep 2014
[TGFB1] Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells, Tripathi, R;Ash, D;Shaha, C;,
J. Cell. Mol. Med. Sep 2014
[ATG5] Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells, Tripathi, R;Ash, D;Shaha, C;,
J. Cell. Mol. Med. Sep 2014
[BECN1] Bile Acids Regulate Nuclear Receptor (Nur77) Expression and Intracellular Location to Control Proliferation and Apoptosis, Hu, Y;Chau, T;Liu, HX;Liao, D;Keane, R;Nie, Y;Yang, H;Wan, YJ;,
Mol. Cancer Res. Sep 2014
* Delivery time is an estimate in business days. Occasional delays may occur due to unforeseen complexities in the preparation of your construct. International customers may expect an additional 1-2 weeks in shipping